Studying DNA in Samples From Younger Patients With Down Syndrome and Acute Myeloid Leukemia Treated on COG-AAML0431 Clinical Trial
RATIONALE: Studying samples of blood, tissue, and bone marrow from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
PURPOSE: This research trial studies DNA samples from patients with Down syndrome and acute myeloid leukemia treated on COG-AAML0431 clinical trial.
Genetic: gene mapping
Genetic: microarray analysis
Genetic: mutation analysis
Genetic: nucleic acid sequencing
Other: laboratory biomarker analysis
|Study Design:||Observational Model: Case-Only
Time Perspective: Retrospective
|Official Title:||Whole Exon Sequencing of Down Syndrome Acute Myeloid Leukemia|
- Identification of unique mutations through whole-genome sequencing [ Designated as safety issue: No ]
|Study Start Date:||February 2012|
|Primary Completion Date:||May 2016 (Final data collection date for primary outcome measure)|
- To identify new genetic abnormalities associated with acute myeloid leukemia (AML) in patients with Down syndrome through whole-genome sequencing.
OUTLINE: This is a multicenter study.
Extracted DNA and RNA from cryopreserved specimens are analyzed for genomic sequencing, gene mutation, and microarray analysis.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01507441
|Principal Investigator:||Jeffrey Taub, MD||Children's Hospital of Michigan|